Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Therapie|February 28, 2021
[An example of Clinical Investigations Center reorganization during the COVID-19 pandemic French national lockdown]Zineb Ghrieb, Souhil Allaoua, Jin Huang, et al.
The Lancet. Haematology|March 25, 2021
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trialAntonio M Risitano, Alexander Röth, Juliette Soret, et al.
Molecular Cancer Therapeutics|April 19, 2024
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia TreatmentManuela Bratti, Elisa Stubbs, Sergii Kolodych, et al.
Annals of Neurology|April 8, 2009
TARDBP mutations in motoneuron disease with frontotemporal lobar degenerationLina Benajiba, Isabelle Le Ber, Agnès Camuzat, et al.
EMBO Reports|June 11, 2025
AML patient blasts exhibit polarization defects upon interaction with bone marrow stromal cellsKhansa Saadallah, Benoît Vianay, Louise Bonnemay, et al.
American Journal of Hematology|January 27, 2024
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PMMatteo Guerra, Hélène Pasquer, Rafael Daltro de Oliveira, et al.
Cancer Discovery|April 11, 2022
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML BlastsJana M Ellegast, Gabriela Alexe, Amanda Hamze, et al.
Journal of Cancer|March 26, 2014
Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in ConsolidationGuillemette Fouquet, Benjamin Hebraud, Sylvain Garciaz, et al.
Nature Medicine|February 14, 2017
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemiaNina Fenouille, Christopher F Bassil, Issam Ben-Sahra, et al.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Pageof 4